Advertisement

FDA grants priority review for Alzheimer's drug Lecanemab, say Eisai, Biogen

The FDA accepted Eisai's supplemental Biologics License Application for the drug, supporting the transition from the accelerated approval granted in January

Advertisement
|Mar 06, 2023, 14:02:06 IST

Tokyo: Japanese drugmaker Eisai Co Ltd and its US partner Biogen Inc said on Monday that the US Food and Drug Administration granted priority review for traditional approval of their Alzheimer's treatment Lecanemab.The FDA accepted Eisai's supplemental Biologics License Application for the drug, supporting the transition from the accelerated approval granted in January, the drugmaker said in a statement.Read all the Latest News, Trending NewsCricket News, Bollywood News,India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Advertisement
Handpicked stories, in your inbox
Global stories. Indian perspective. Zero noise.
No Spam. Unsubscribe Any Time.
First Published:Mar 06, 2023, 14:02:06 IST
Advertisement
Advertisement
Trending Stories

Pakistan's deep state weaponising LeT to counter Asim Munir critic Maulana Fazlur Rehman: Report

A deepening military-terror nexus is reportedly emerging in Pakistan in a bid to neutralise the JUI-F chief, Maulana Fazlur Rehman, after he openly criticised Pakistan's Army Chief Asim Munir.
2 min read
Advertisement
Advertisement
Up Next